Естонија - Естонски - Ravimiamet

virbac - koerte katku elusviirusvaktsiin+koerte elus parvoviirusvaktsiin+koerte nakkava hepatiidi elusviirusvaktsiin+koerte paragripi elusviirusvaktsiin - süstesuspensiooni lüofilisaat ja lahusti - 1annus 1annus 50tk; 1annus 1annus 10tk

Естонија - Естонски - Ravimiamet

merial - koerte katku elusviirusvaktsiin+koerte elus parvoviirusvaktsiin+koerte nakkava hepatiidi elusviirusvaktsiin+koerte paragripi elusviirusvaktsiin - süstesuspensiooni pulber ja lahusti - 10000ccid50+0+0+0 1annus 1annus 10tk; 10000ccid50+0+0+0 1annus 1annus 1tk

Естонија - Естонски - Ravimiamet

sandoz pharmaceuticals d.d. - lamivudiin+abakaviir - õhukese polümeerikattega tablett - 300mg+600mg 60tk; 300mg+600mg 30tk; 300mg+600mg 90tk

Естонија - Естонски - Ravimiamet

viatris limited - lamivudiin+abakaviir - õhukese polümeerikattega tablett - 300mg+600mg 30tk; 300mg+600mg 90tk

Естонија - Естонски - Ravimiamet

zentiva k.s. - lamivudiin+abakaviir - õhukese polümeerikattega tablett - 300mg+600mg 30tk

Естонија - Естонски - Ravimiamet

teva b.v. - bortesomiib - süstelahuse pulber - 3,5mg 1tk

Естонија - Естонски - Ravimiamet

stada arzneimittel ag - bortesomiib - süstelahus - 2,5mg 1ml 1.4ml 1tk; 2,5mg 1ml 2.8ml 1tk

Европска Унија - Естонски - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Европска Унија - Естонски - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatiit, atoopiline - muud dermatoloogilised preparaadid - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Естонија - Естонски - Ravimiamet

egis pharmaceuticals plc - atorvastatiin+esetimiib - kõvakapsel - 10mg+10mg 30tk; 10mg+10mg 90tk; 10mg+10mg 100tk; 10mg+10mg 60tk; 10mg+10mg 120tk; 10mg+10mg 80tk; 10mg+10mg 70tk